Trivalent Influenza Vaccines Will Be Delivered for the 2024-2025 Flu Season

CSL Seqirus today announced that it is fully equipped to deliver its influenza vaccine portfolio for the 2024-2025 U.S. season.

The new vaccine will be based on the trivalent strains recommended by the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC), which confirmed the viral strain selection in a March 5, 2024 meeting.

Furthermore, CSL Seqirus has already received FDA approval for its U.S. trivalent influenza vaccines. 

"CSL Seqirus applauds the VRBPAC's commitment to providing a clear, evidence-backed recommendation to the FDA so that the composition of seasonal influenza vaccines for the upcoming season will be formulated to match projected circulating strains, based on the WHO's ongoing surveillance," said Gregg Sylvester, CSL Seqirus's Chief Health Officer and Head of Medical Affairs, in a press release.

"In addition to implementing this change, we are committed to working with our partners in public health to reverse the alarming decline in immunization rates and vaccine confidence that we have seen over the past two flu seasons."

The strain selection for the 2024/25 influenza season reflects the removal of B/Yamagata, which will not be included in the vaccines manufactured and delivered by CSL Seqirus. 

This selection is in accordance with the February 2024 World Health Organization recommendations and is identical to the Southern Hemisphere 2024 flu season, which usually occurs between April and September.

On March 4, 2024, the WHO published Influenza Update N° 466, confirming influenza detections have recently decreased in the Northern Hemisphere.

"This strain consistency across hemispheres will support both speed and efficiency, as CSL Seqirus has experience manufacturing these recommended strains," commented Dave Ross, Vice President of North America Commercial Operations, CSL Seqirus. 

Across the globe, CSL Seqirus is collaborating with regulatory bodies and public health authorities on an appropriate transition timeline for each country, which aims to ensure a smooth transition, increase vaccine confidence, and improve immunization rates.

CSL Seqirus is one of the largest influenza vaccine providers in the world. It utilizes egg, cell, and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries worldwide.

As of late February 2024, the U.S. CDC reported over 158 million flu vaccines had been distributed during the 2023-2024 season.

Various flu shots remain available at most pharmacies in the U.S.